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Abstract
The study of subjective, first-person experience is a topic with both philosophical and practical im-
plications. In this article, I discuss the value of collecting a critical mass of prose or verbal descriptions
of introspectively determined, subjective effects of pharmacological agents. I suggest that datasets of
introspective reports fit in the modern research landscape at the intersection of biomedical informatics
and the emerging discipline of contemplative neuroscience. I compare the current proposal to Descrip-
tive Experience Sampling (DES), discuss relevant methodological and conceptual issues in the study of
introspection, and provide a list of questions for directing future investigation.
1 Introduction
Pharmacology is a cornerstone of modern medicine. To minimize the likelihood of drugs with adverse side
effects reaching the public, multiple stages of safeguards, including animal models and post-marketing ob-
servational studies are used.
Drugs with side effects can broadly (and informally) be divided into two categories. Those which are toxic
and cause severe physiological damage to an individual (or a fetus in utero, as in the case of thalidomide),
and those whose side effects are non-lethal, but which are sufficiently unpleasant to make the drug an inviable
candidate to be released to the market. For instance, a pain killer which completely attenuates migraines
and causes severe but temporary abdominal pain is unlikely to be preferred over one that simply reduced
the intensity of the migraine by 60% and had no other adverse effects.
Philosophically, there is a clear difference between these two categories. The first consists of effects that can
be objectively verified by a third party observer, whereas the latter consists of introspective reports from
the subject. In other words, this category consists of side effects (or simply effects) which relate to the inner
experience of taking a drug. Consequently, to the extent that we have any information about the subjective
experience of pharmacological effects and side-effects, they are restricted to cases of severe, or at the very
least negative and unpleasant, side-effects. However, it is worth considering if there might be benefits to
extending this knowledge-base to include more subtle effects of a drug (whether psychoactive or otherwise)
and to make introspection a significant tool of investigation in modern pharmacology.
The present article relates to two contemporary areas of modern science and medicine. The first is the
rapidly growing discipline of contemplative neuroscience. The aim of this discipline is to take an individ-
ual’s subjective experience as the basic object of scientific scrutiny. Whether in the context of fundamental
research pursued by philosophers and cognitive scientists, or with the aim of introducing introspective ideas
into medical practice at centers for integrative medicine, many introspective traditions from around the world
are finding their way into modern science [Barnes et al., 2004, Brown and Ryan, 2003, Carlson et al., 2003,
Davidson et al., 2003, Kabat-Zinn, 2003, Lazar et al., 2005, Lutz and Thompson, 2003, Lutz et al., 2004,
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Ott et al., 2006, Shapiro et al., 1998, Harrington and Zajonc, 2008].
The second is the use of modern machine learning and data analytic tools in the biomedical research pipeline.
The massive size of the biomedical literature, the existence of forums on the Internet where individuals re-
port side-effects, and the availability of datasets of search queries, have enabled researchers to use completely
data-driven techniques to uncover effects that were overlooked by the traditional methods of pharmacology
and pharmaco-epidemiology [Bishop, 2007, Abu-Mostafa et al., 2012, Chen et al., 2007, Tatonetti et al.,
2012, Percha et al., 2012]1.
The synthesis of these efforts would be large databases consisting of prose descriptions of introspective
reports of pharmacological agents. These databases would not need to be restricted to drugs whose primary
function is psychoactive. The thesis of the present article is that such databases would be valuable for
all categories of drugs, whether pain killers, chemotherapy, statins, or herbal supplements. In addition to
detailed descriptions, there are a range of simple questions one can easily ask about the internal experience
of drugs that could prove to be useful when collected at a large scale. For instance, determining which
compounds have introspectively noticeable effects at all is the most basic question one can ask. I consider
this and other questions in the subsequent sections.
2 Contemplative Neuroscience
As pharmacology needs little introduction as a discipline, I begin with a brief discussion of contemplative
neuroscience (or contemplative studies) and an overview of some contemporary research. The fundamental
aim of these emerging topics of study is to bridge the knowledge of introspective traditions with modern
neuroscience. Many areas of modern psychology and cognitive science study introspection and subjective
experience to limited degrees. However, the aim of contemplative neuroscience is to take individuals’ subjec-
tive experience and the dimensions of their inner life as the basic objects of scientific scrutiny [Varela, 1996,
Harrington and Zajonc, 2008, Lutz and Thompson, 2003].
Introspection is not a new idea, and much of the knowledge that has driven modern contemplative neuro-
science originates from traditions that extend back many centuries. These traditions include yoga, Tai Chi,
Zen, and Tibetan Buddhism, to name just a few. While those from medically oriented communities are often
interested in how contemplative techniques can influence patient outcomes and quality of life, particularly in
the case of chronic pain or terminal illnesses [Ott et al., 2006, Sherman et al., 2005], a substantial amount of
research has also taken place in the basic research setting. Modern imaging techniques and electrophysiology,
such as fMRI, MEG, and EEG, have played a crucial role in these areas of research, allowing investigators
to characterize the long and short-term changes taking place in the brains of advanced meditators who have
devoted many thousands of hours to the practice of introspective techniques, or short-term interventions in
novices. [Davidson et al., 2003, Lazar et al., 2005, Lutz et al., 2004].
However, in spite of the substantial growth of contemplative neuroscience, it is still a subject in its infancy,
and there is certainly low-hanging fruit which has yet to be examined. In the remainder of the article, I
will argue for the integration of pharmacology, introspection, and data-science as an important avenue for
fundamental research.
1There are also commercial efforts taking advantage of these techniques, an area that is likely to grow substantially in the
coming years. See, for example, Iodine, which uses crowdsourcing and predictive models to help patients find appropriate
medications for their conditions with maximal efficacy and minimal side-effects.
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3 Motivating Questions
The primary aim of this article is to advocate for a certain type of study, or data collection endeavor. While
the idea is simply stated, a number of conceptual and methodological questions naturally arise that would
need to be addressed before proceeding further. Therefore, as a means to communicate this perspective, I
have included below a list of questions to motivate additional investigation.
I have divided the questions into two categories. The first consists of basic questions about the subjective
effects of pharmacological agents, i.e. what the late philosopher and contemplative neuroscience pioneer
Francisco Varela termed “neuro-phenomenology” [Lutz and Thompson, 2003, Varela, 1996]. The second
consists of methodological questions that might arise in attempting to collect this data.
Fundamental Questions
• What is the minimum dosage at which a drug is noticeable?
• What exogenous factors influence a person’s ability to notice a drug? What about drug-drug interac-
tions? To what extent is a person’s ability to notice a drug related to their genotype for enzymes in
the cytochrome P450 system, such as CYP2D6 [Atkinson Jr et al., 2012]?
• Is there a physiological analogue to perceptual adaptation [Moradi et al., 2005]? That is, are there
certain drugs which make others more noticeable? For example, is someone who just took a large dose
of caffeine more likely to notice a microdose of alcohol?
• In a large group of subjects, what is the distribution of minimum values at which a drug is noticeable?
Can we explain why the distribution looks the way it does?
• Are there drugs, such as ordinary pain killers, that are not noticeable even at high dosages? That is, if
a subject who was not in any pain took an ordinary pain killer (i.e., one that is not an opiate), would
they be able to notice it? What is the minimum dosage?
• Suppose we have two drugs which are both noticeable at some level. Are they discriminable from
each other? That is, if a person is told that they are being given either drug A or drug B at the
minimum noticeable dose, are they able to detect which one they were administered? How reliably?
What accounts for the variation in a person’s ability to detect a drug when administered blindly?
• What is the best predictor of the level at which a drug is noticeable to an individual?
• How do body-oriented introspective practices, such as Tai Chi, yoga, Alexander Technique, among
others, impact a person’s ability to notice small doses of a drug [Gard et al., 2011, Kerr et al., 2008,
Mehling et al., 2005, Sherman et al., 2005, Price, 2005, Ives, 2003, Klein et al., 2014, Mehling, 2001,
Smith et al., 1999]? How do these relate to meditation [Lazar et al., 2005, Harrington and Zajonc,
2008]?
• Suppose that we are able to determine, for a given individual, the minimum noticeable dosages for a
wide variety of drugs. Do these values form a distinct signature of the person? Are there are other
physiological variables that such a signature is a strong predictor of?
• Suppose that we have detailed prose descriptions of the effects of many classes of drugs from many
individuals. Do they form natural clusters? How do the clusters determined informally by investigators
relate to those identified by standard clustering techniques from machine learning [Bishop, 2007, Abu-




• What are the ethical issues that arise in collecting introspective reports of pharmacological agents?
How will collecting this data fit into existing practices overseen by Institutional Review Boards?
• How reliable are introspective reports? What is the variation over time of a given individual’s reports?
Do past experiences shape a person’s response to microdoses of a drug?
• Are there methods for eliciting more reliable introspective reports? What about techniques for training
a person to notice the effects of a drug?
• Are there other modalities for recording introspective observations? For instance, as machine learning
and data analytic capabilities become increasingly powerful and capable of handling larger and larger
datasets, will audio and video recordings prove to be a more powerful modality? Or is the additional
information mostly extraneous relative to prose descriptions?
• Do we have an adequate vocabulary for capturing the subtle effects of a drug on the body and mind?
Are the insights of long-standing introspective traditions relevant to improving a person’s ability to
capture the internal experience of a particular drug?
• Collecting the necessary data, such as determining the minimum noticeable dosages of a wide variety
of compounds, would be a fairly involved process, and likely have more in common with extended sleep
studies in a hospital setting, rather than the short, and easily administered psychophysics experiments
conducted at university cognitive science departments. What are the practical obstacles to conducting
studies of this kind? What lessons can we learn from related studies that have been conducted before?
3.1 Descriptive Experience Sampling
Some of the above questions overlap with existing methodologies and research efforts in contemplative neuro-
science. I will briefly discuss one of them, namely, the technique of Descriptive Experience Sampling (DES).
The aim of DES is to capture the internal experiences of individuals in a minimally invasive, naturalistic
setting and to provide a large body of information for advancing contemplative neuroscience. In DES, sub-
jects wear a device which beeps at random intervals. When the device beeps, subjects are instructed to write
down everything they were experiencing in that moment [Hurlbut and Schwitzgebel, 2007, Engelbert and
Carruthers, 2011].
The present proposal is related to DES, although the aim is to capture a much narrower type of informa-
tion, rather than the entirety of what a person is experiencing in a given moment. It is worth mentioning
several of the criticisms that have been raised about DES and how they relate to collecting introspective
information about pharmacological effects. Broadly speaking, DES has been criticized for producing re-
ports of questionable validity after probing by an investigator. That is, people may in one moment report
thinking one set of thoughts, or having one set of experiences, and then change their mind after the fact
when asked pointed questions. In addition, some researchers have highlighted the difficulty subjects face
in simultaneously experiencing and reporting a subjective state, and the inherent ambiguity in forming an
explicit linguistic representation of a subjective experience [Hurlbut and Schwitzgebel, 2007, Engelbert and
Carruthers, 2011].
The questions I have raised above may circumvent the possible complications of DES. In particular, critics
of DES grant that the technique can be reliable when restricted to gross aspects of sensory experience, such
as simply noticing that one is in pain, or observing the color of an object. A number of the above questions
involve merely detecting that a microdose of a compound had been administered relative to a placebo, and
not characterizing the evolution of ongoing mental states. If, on the other hand, one attempted to understand
how a particular drug impacted a person’s inner life in a naturalistic setting—certainly an important lines
of questioning—then the complications of the DES methodology would be relevant.
4
4 Conclusion
The aim of this article is to argue that research integrating data science, contemplative neuroscience, and
pharmacology is of both philosophical and practical significance. To motivate possible research directions
that lie at the intersection of these three disciplines, I propose several questions relating to the subjective
experience of pharmacological agents. For instance, understanding the reliability of introspective observation
and recall has been a significant area of debate in contemplative neuroscience, and continues to be an active
area of research and investigation. In situations where ancient contemplative practices have insights that are
relevant to modern science, barriers of cross-cultural understanding must also be traversed. The questions
that I have asked above relating to minimum noticeable dosages (MNDs) circumvent some complications
that arise in collecting reliable introspective reports.
Large data sets of introspective reports of pharmacological agents—whether prose descriptions or binary
variables (e.g. noticeable / not-noticeable)—will be useful for a variety of reasons. Practically, such data
sets will be a valuable resource for exploratory data analysis. For instance, knowledge of the minimum no-
ticeable dosages for a wide variety of compounds may allow us to predict drug-drug interactions. Predictive
models developed using data from introspective reports could enable us to predict non-lethal or unpleasant
side-effects of novel drug. A large number of minimum noticeable dosages might encode a distinct, physiolog-
ical signature of a person. If so, such a signature could be a valuable predictor of other medically important
parameters.
Finally, exploratory data analysis on large bodies of introspective reports may play an important role in
advancing the fundamental methodology and basic knowledge of contemplative neuroscience. The systematic
study of introspection is in its nascent stages and many basic methodological issues are just now being
explored. There is much to be gained from additional interaction between these communities and medical
investigators. Furthermore, utilizing data science to analyze introspective reports by both lay individuals as
well as those highly trained in introspective techniques may allow us to move beyond uncovering unpleasant
side-effects, develop a more sophisticated understanding of inner experience, and systematize taxonomies
from prose descriptions.
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